Scinovia

Point-and-Image to Know-the-Flow

Scinovia

Point-and-Image to Know-the-Flow

Raleigh, NC
Health Tech
Scinovia’s mission is to produce state-of-the-art diagnostics to help doctors make more data-driven decisions during procedures to save more lives. Scinovia developed VUFLOW, the future of non-contact imaging diagnostics for blood flow during surgery.

$78,434

raised
36
Investors
$89.3M
Valuation
$2.85
Price per Share
$498.75
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering

$78,434

raised
36
Investors
$89.3M
Valuation
$2.85
Price per Share
$498.75
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering

Rewards

Get rewarded for investing more into Scinovia:

$498+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,500+
Investment
$1,500+ Tier
Invest $1,500+ and receive 15% bonus shares
$5,000+
Investment
$5,000+ Tier
Invest $5,000+ and receive 20% bonus shares
$25,000+
Investment
$25,000+ Tier
Invest $25,000+ and receive 25% bonus shares
$50,000+
Investment
$50,000+ Tier
Invest $50,000+ and receive 30% bonus shares
$100,000+
Investment
$100,000+ Tier
Invest $100,000+ and receive 40% bonus shares

Reasons to Invest

Save more lives: A big challenge many surgeons face is knowing if procedures have optimal blood flow for quick recovery.
Disrupt a $500M market: Displace legacy contact probe* and dye* methods over past 60 years with VUFLOW, one of the first non-contact measurement device to visualize blood flow speeds in surface vessels during major surgeries.
Platform Technology: VUFLOW may be applicable to many types of surgeries. There are over 300M per year. Initial markets are heart bypass and organ transplants.

OVERVIEW


MedTech imaging for non-contact visualization of blood flow

Scinovia Corp. is a medtech company engaged in the development of proprietary, non-contact diagnostics for cardiovascular and vascular surgeries with the aim to enhance patient outcomes, making surgeries safer and more cost-effective. We focus on improving outcomes of heart bypass, revascularization, and organ transplant therapies where blood flow is key to recovery and to reduce death and costly complications.


Scinovia is entering a growing market of $500M in sales last year with a revolutionary device VUFLOW that provides non-contact, real-time, quantitative data. Presently, the market relies on contact methods that were developed 60 years ago.


Our product roadmap includes a robotic-assisted diagnostic to enhance ease of use and precision while visualizing blood flow during surgery.

Scinovia is a pre-revenue, FDA registered company. VUFLOW units are being scheduled to enter hospitals in 2022 to explore diverse therapeutic areas and generate revenue


Product Use Video:



THE PROBLEM


Assessing the blood flow for surgery is challenging and costly

1. A top challenge surgeons face is knowing whether a procedure has poor blood flow.

The number one problem surgeons face is knowing whether a procedure has poor blood flow. 20% of bypass grafts have less than 
50% of average blood flow and 14% of breast reconstruction have necrosis. These cases add up: it costs around $100k per case to address breast tissue necrosis.


Source | Source



2. Current tools require contact and have challenges.






THE SOLUTION


Know-the-flow in real-time with VU-FLOW

Case studies have shown visualizing blood flow during surgeries can substantially assist in predicting if poor outcomes may occur. Poor outcomes result in longer recovery for people, costly complications, re-admissions, re-operations, or death.We designed VUFLOW to be the first non-contact visualization tool. Surgeons can now point-n-image to visualize blood flow.

*Computer generated animation for optional robotic upgrade in 2022




Business Model

Software as a Service will be offered on a pay-per-case basis and a multi-year subscription will be offered at a discount, which can be used to help capitalize sales growth. The data acquisition hardware will undergo periodic upgrades to keep up with new visualization features.


The cost for the first 7 units have been paid. We plan to fund operations through raising capital, selling subscriptions, and leveraging credit facilities through financial services in the MedTech industry. 



We plan to grow based on net income, use credit facilities to cover costs over the 4 month gap from building units to selling subscriptions.


First 2 rows indicate capability to assess blood flow speeds. The last 3 rows indicate safety elements.





THE MARKET


300 million major surgeries are being performed annually

Doctors use contact devices to measure blood flow speeds in over 300,000 cases per year. However, an average of 300 million major procedures are performed annually. The global market is estimated to be over $500M in annual sales.


A market comp Novadaq sold fluorescent angiography devices and was acquired by Stryker for $701M, 7 years after its market cap was approximately $100M on NASDAQ.




OUR TRACTION


Scheduling clinical studies

Scinovia is an FDA registered manufacturer. Several VU-FLOW units are being scheduled for comparative clinical studies in early 2022. This represents an opportunity for VUFLOW to be published, become known among the societies and conferences, and to assess various indications for potential regulatory clearance.


Surgeons from diverse therapies, e.g., bypass, vascular, plastics, cancer, and emergency rooms have shown strong interest in exploring ways that VUFLOW could help in various procedures.



Scinovia is currently integrating a robotic assisted option that will auto-adjust imaging to reduce glare and improve precision and ease-of-use.



WHY INVEST


Join a game-changing company

We aim to innovate and provide doctors with better tools to improve outcomes for loved ones. We’re targeting existing users of contact devices to switch to our revolutionary non-contact VUFLOW. Last year, hospitals spent over $500M on contact devices.


Our goal is for VUFLOW, which is a platform technology, to become an appliance that is used across many types of procedures.




Emoticons

In the Press

Inkwood Research

CEO OF SCINOVIA’S TAKE ON THE BLOOD FLOW MEASUREMENT DEVICES MARKET

North Carolina Biotechnology Center

Scinovia Developing Blood-flow Imaging System for Heart Bypass Surgeries

WRAL TechWire

Durham startup aims to raise $6M for blood-flow monitoring system

NC Business News Wire

Start-up Scinovia looking to change how blood flow is measured during surgery

Offering Summary


Company

:

Scinovia Corp.

Corporate Address

:

8801 Fast Park Dr, STE 301, Raleigh, NC 27617

Offering Minimum

:

$9,997.80

Offering Maximum

:

$1,069,998.30

Minimum Investment Amount

(per investor)

:

$498.75











Terms


Offering Type

:

Equity

Security Name

:

Class C Nonvoting Common Stock

Minimum Number of Shares Offered

:

3,508

Maximum Number of Shares Offered

:

375,438

Price per Share

:

$2.85

Pre-Money Valuation

:

$89,293,381.35











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Time-Based:

Friends & Family Early Birds Bonus:

Invest within the first 72 hours and receive 20% bonus shares

Super Early Bird Bonus

Invest within the next 72 hours and receive 15% bonus shares

Early Bird Bonus

Invest within the next 7 days and receive 12% bonus shares

Amount-Based:

Invest $1,500+: Receive 15% bonus shares

Invest $5,000+: Receive 20% bonus shares

Invest $25,000+: Receive 25% bonus shares

Invest $50,000+: Receive 30% bonus shares

Invest $100,000+: Receive 40% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Scinovia Corp. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class C Nonvoting Common Stock at $2.85 / share, you will receive 110 shares of Class C Nonvoting Common Stock, meaning you'll own 110 shares for $285. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”. Vendor payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$1,391,603.00 USD
$1,360,287.00 USD
Cash And Cash Equivalents
$140,305.00 USD
$279,741.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$190,379.00 USD
$223,528.00 USD
Long Term Debt
$50,768.00 USD
$64,566.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$748,794.00 USD
-$588,679.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Alien TT invites Scinovia to pursue large EIC grants

21 hours ago

AlienTT invites Scinovia to pursue European Innovation Council (EIC) Accelerator grants, which is endowed with EUR 1B


Jan 4, 2022 Yahoo! Finance article

16 days ago

"This Company is Revolutionizing Blood Flow Visualization During Surgery"


"Our hospitals are a far cry from the days ..."



Scinovia Launch Announcement

29 days ago

Please share ...
Scinovia launches crowdfunding campaign on
StartEngine for commercialization

INVEST NOW


Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}